menu
    • menu
    [{"orgOrder":0,"company":"Forty Seven","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"Magrolimab","moa":"Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase II","graph3":"Forty Seven","amount2":4.9000000000000004,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":4.9000000000000004,"dosageForm":"Undisclosed","sponsorNew":"Forty Seven \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Forty Seven \/ Gilead Sciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Forty Seven

    Menu

    Forty Seven

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Forty Seven

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Forty Seven

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Magrolimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Gilead Sciences

                            Deal Size : $4,900.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Gilead to Acquire Forty Seven for $4.9 Billion

                            Details : Gilead gains Forty Seven’s investigational immuno-oncology therapy in multiple clinical studies, supporting its strategic focus in oncology as well as innovative pipeline.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : $4,900.0 million

                            March 02, 2020

                            Lead Product(s) : Magrolimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Gilead Sciences

                            Deal Size : $4,900.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth